Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMV1408)

Drug Name
SU5403 Drug Info
Synonyms
189894-57-3; 1-((1S,2S)-1-Hydroxy-1-(4-hydroxyphenyl)propan-2-yl)-4-phenylpiperidin-4-ol methanesulfonate trihydrate; UNII-BD2A56I30W; BD2A56I30W; Traxoprodil mesylate, CP-101606-27; Traxoprodil mesylate [USAN:INN]; (1S,2S)-1-(4-HYDROXYPHENYL)-2-(4-HYDROXY-4-PHENYLPIPERIDIN-1-YL)-1-PROPANOL METHANESULFONATE TRIHYDRATE; Traxoprodil mesylate hydrate; CHEMBL3989673; KS-00000REE; MolPort-023-219-113; AKOS025396623; RL02411; DS-5988; BCP9000543
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9826324
CAS Number
CAS 189894-57-3
TTD Drug ID
DMV1408

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Fibroblast growth factor receptor (FGFR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Erdafitinib DMI782S Bladder cancer 2C94 Approved [2]
Futibatinib DMWM4D0 Intrahepatic cholangiocarcinoma 2C12.10 Approved [3]
Infigratinib DMNKBEC Cholangiocarcinoma 2C12.10 Approved [4]
HIF-1alpha DM4OQRD Lymphoma 2A80-2A86 Phase 4 [1]
ARQ-087 DM02BVQ Intrahepatic cholangiocarcinoma 2C12.10 Phase 3 [4]
AZD4547 DM3827C Solid tumour/cancer 2A00-2F9Z Phase 2/3 [4]
Debio 1347 DMZW50O Solid tumour/cancer 2A00-2F9Z Phase 2 [5]
BAY1163877 DMCSGJ2 Bladder cancer 2C94 Phase 2 [6]
ICP-192 DM524GR Bladder cancer 2C94 Phase 2 [7]
PRN1371 DMR7BAO Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fibroblast growth factor receptor (FGFR) TT0LF7H NOUNIPROTAC Antagonist [1]

References

1 Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
3 TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities. Molecular Cancer Therapeutics. 01/2014; 12(11_Supplement):A270-A270.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther. 2014 Nov;13(11):2547-58.
6 Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial. Cancer Research. 10/2014; 74(19 Supplement):1739-1739.
7 Clinical pipeline report, company report or official report of InnoCare Pharma.